Phaseline

Companies › Akero Therapeutics

Akero Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 3; Gastroenterology; next expected readout Feb 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Efruxifermin
FGF21 receptor agonist
FGF21Phase 3NASH/MASH; NASH - Nonalcoholic Steatohepatitis; NASH With FibrosisFeb 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06161571EfruxiferminPhase 3NASH/MASHGastroenterologyMar 2026
NCT06528314EfruxiferminPhase 3NASH - Nonalcoholic SteatohepatitisGastroenterologyFeb 2030
NCT06215716EfruxiferminPhase 3NASH With FibrosisGastroenterologyFeb 2033

Targets

FGF21 (1)

Companies with the same targets

GSK Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical

Companies built like this

Pharmicell Camurus VectivBio LyGenesis Mikrobiomik Healthcare Company

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.